Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients

기사 요약

Imunon reports early Phase 2 data showing lower residual disease and higher ctDNA clearance with IMNN-001 in ovarian cancer.